

Elena Quaglino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6296422/publications.pdf>

Version: 2024-02-01

61
papers

2,656
citations

201674

27
h-index

182427

51
g-index

62
all docs

62
docs citations

62
times ranked

3765
citing authors

#	ARTICLE	IF	CITATIONS
1	Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy. <i>Cells</i> , 2022, 11, 172.	4.1	4
2	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. <i>Biomedicines</i> , 2022, 10, 230.	3.2	1
3	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
4	Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. <i>Oncolmmunology</i> , 2022, 11, .	4.6	12
5	Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2321.	4.1	16
6	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 894.	3.7	6
7	Breast cancer stem cell antigens as targets for immunotherapy. <i>Seminars in Immunology</i> , 2020, 47, 101386.	5.6	48
8	Cancer stem cell antigens as targets for new combined anti-cancer therapies. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 129, 105861.	2.8	12
9	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1039-1053.	3.4	26
10	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. <i>Vaccines</i> , 2020, 8, 166.	4.4	1
11	Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 131-141.	4.2	37
12	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1839-1853.	4.2	34
13	â€˜In Vitroâ€™, â€˜In Vivoâ€™ and â€˜In Silicoâ€™ Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector. <i>Pharmaceutical Research</i> , 2018, 35, 75.	3.5	16
14	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	4.1	33
15	CSPG4: a prototype oncoantigen for translational immunotherapy studies. <i>Journal of Translational Medicine</i> , 2017, 15, 151.	4.4	51
16	Protection of mice against the highly pathogenic VVHJD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. <i>Antiviral Research</i> , 2016, 134, 182-191.	4.1	3
17	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl-âˆ²-cyclodextrin complex and resveratrol suspension after oral administration. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2016, 86, 263-271.	1.6	12
18	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2016, 5, e1253653.	4.6	30

#	ARTICLE	IF	CITATIONS
19	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. <i>Oncolmmunology</i> , 2016, 5, e1082705.	4.6	9
20	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2+ mammary cancer. <i>Plant Biotechnology Journal</i> , 2016, 14, 153-159.	8.3	12
21	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	4.4	38
22	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. <i>Laboratory Investigation</i> , 2015, 95, 561-571.	3.7	30
23	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. <i>Oncolmmunology</i> , 2015, 4, e1005500.	4.6	12
24	2H,3H-Decafluoropentane-Based Nanodroplets: New Perspectives for Oxygen Delivery to Hypoxic Cutaneous Tissues. <i>PLoS ONE</i> , 2015, 10, e0119769.	2.5	39
25	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. <i>Journal of Immunology</i> , 2014, 192, 5434-5441.	0.8	16
26	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014, 20, 3753-3762.	7.0	64
27	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	5.0	27
28	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 99-122.	1.1	10
29	Ultrasound-activated decafluoropentane-cored and chitosan-shelled nanodroplets for oxygen delivery to hypoxic cutaneous tissues. <i>RSC Advances</i> , 2014, 4, 38433-38441.	3.6	39
30	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014, 15, S1.	2.8	20
31	miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2. <i>American Journal of Pathology</i> , 2013, 182, 2058-2070.	3.8	52
32	miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. <i>FASEB Journal</i> , 2013, 27, 1223-1235.	0.5	134
33	Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. <i>Frontiers in Oncology</i> , 2013, 3, 122.	2.8	27
34	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. <i>Oncolmmunology</i> , 2013, 2, e26137.	4.6	27
35	miR-214 Coordinates Melanoma Progression by Upregulating ALCAM through TFAP2 and miR-148b Downmodulation. <i>Cancer Research</i> , 2013, 73, 4098-4111.	0.9	87
36	Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD). <i>PLoS ONE</i> , 2013, 8, e58358.	2.5	7

#	ARTICLE	IF	CITATIONS
37	DNA vaccination against oncoantigens. <i>Oncolmunology</i> , 2012, 1, 316-325.	4.6	34
38	Met Receptor Acts Uniquely for Survival and Morphogenesis of EGFR-Dependent Normal Mammary Epithelial and Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e44982.	2.5	16
39	microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. <i>EMBO Journal</i> , 2011, 30, 1990-2007.	7.8	228
40	HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2011, 89, 1231-1240.	3.9	12
41	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. <i>Cancers</i> , 2011, 3, 3225-3241.	3.7	21
42	Oncoantigens for an immune prevention of cancer. <i>American Journal of Cancer Research</i> , 2011, 1, 255-264.	1.4	4
43	Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB2 oncogene. <i>Molecular Carcinogenesis</i> , 2010, 49, 114-120.	2.7	29
44	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	3.6	228
45	Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 119-128.	0.9	39
46	Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten. <i>Cancer Research</i> , 2010, 70, 2558-2567.	0.9	131
47	A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. <i>Cancer Research</i> , 2010, 70, 2604-2612.	0.9	54
48	Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1685-1694.	4.2	13
49	Protective Immunity Against <i>neu</i> -Positive Carcinomas Elicited by Electroporation of Plasmids Encoding Decreasing Fragments of Rat Neu Extracellular Domain. <i>Human Gene Therapy</i> , 2008, 19, 229-240.	2.7	21
50	ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas. <i>Current Protocols in Immunology</i> , 2008, 82, Unit 20.9.1-20.9-10.	3.6	41
51	Immune prevention of mammary carcinogenesis in HER-2/ <i>neu</i> transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	4.2	14
52	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/ <i>neu</i> carcinomas in BALB/c mice. <i>Vaccine</i> , 2005, 23, 3280-3287.	3.8	17
53	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/ <i>neu</i> Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 2858-2864.	0.9	143
54	Concordant morphologic and gene expression data show that a vaccine halts HER-2/ <i>neu</i> preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004, 113, 709-717.	8.2	64

#	ARTICLE	IF	CITATIONS
55	Immunization in tumor prevention. <i>International Immunopharmacology</i> , 2003, 3, 1151-1158.	3.8	4
56	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <i>Journal of Clinical Investigation</i> , 2003, 111, 1161-1170.	8.2	27
57	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. <i>Journal of Clinical Investigation</i> , 2003, 111, 1161-1170.	8.2	105
58	LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. <i>Cancer Research</i> , 2003, 63, 2518-25.	0.9	67
59	Immunological prevention of spontaneous tumors: a new prospect?. <i>Immunology Letters</i> , 2002, 80, 75-79.	2.5	16
60	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2000, 165, 5133-5142.	0.8	326
61	HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies. , 0, , .		3